DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder

[11c]FLUMaZeNIL gabaA-beNZoDIaZepINe receptor bINDINg IN MAjOR DEPRESSIvE DISORDER vERSUS HEALTHY CONTROLS

Identifying Early Maladaptive Schema of Patients with Major Depressive Disorder

Cognitive models of depression propose that negative schemas and Early Maladaptive Schema contribute to depressive symptoms. The purpose of this study is to identify the early maladaptive Schema of patients with depression disorder. The method of study is descriptive. Research statistics involves all patients with depression disorder who have come to the c...

Association study between the Taq1A (rs1800497) polymorphism and schizophrenia in a Brazilian sample Estudo de associação entre o polimorfismo genético Taq1A (rs1800497) e esquizofrenia em uma amostra brasileira

Schizophrenia is a severe psychotic disorder with recurrent relapse and functional impairment. It results from a poorly understood geneenvironment interaction. The Taq1A polymorphism (located in the gene cluster NTAD) is a likely candidate for schizophrenia. Its rs1800497 polymorphism was shown to be associated with DRD2 gene expression. Therefore the present work aims to investigate a possible...

Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls.

OBJECTIVE We aimed to investigate the prevalence of the metabolic syndrome (MetS) and its individual components in subjects with bipolar disorder (BD) compared to those with major depressive disorder (MDD) and non-psychiatric controls. METHODS We examined 2431 participants (mean age 44.3±13.0, 66.1% female), of whom 241 had BD; 1648 had MDD; and 542 were non-psychiatric controls. The MetS was...

Urinary neopterine levels in patients with major depressive disorder: alterations after treatment with paroxetine and comparison with healthy controls.

BACKGROUND A close relationship has been shown between mood disorders and pteridine levels. The aim of this study was to examine alterations in the urine neopterine levels of patients with major depressive disorder (MDD) who responded to paroxetine during the initial treatment and to compare their levels to those of healthy controls. SUBJECTS AND METHODS Sixteen patients with major depression...